Ascendiant Capital Markets Increases Pro-Dex (NASDAQ:PDEX) Price Target to $30.00

Pro-Dex (NASDAQ:PDEX) had its target price upped by equities research analysts at Ascendiant Capital Markets from $28.00 to $30.00 in a research note issued on Monday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Ascendiant Capital Markets’ target price indicates a potential upside of 10.95% from the company’s previous close.

Separately, StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday.

Pro-Dex Trading Up 2.1 %

NASDAQ PDEX opened at $27.04 on Monday. Pro-Dex has a fifty-two week low of $14.51 and a fifty-two week high of $27.60. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.66 and a current ratio of 2.84. The stock has a 50 day simple moving average of $20.07 and a two-hundred day simple moving average of $19.01. The stock has a market cap of $90.85 million, a P/E ratio of 46.62 and a beta of 0.38.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, September 5th. The medical instruments supplier reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.11. Pro-Dex had a return on equity of 6.82% and a net margin of 3.95%. The business had revenue of $15.03 million during the quarter.

Insider Transactions at Pro-Dex

In other news, Director Angelita Rebamontan Domingo sold 2,585 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $18.30, for a total value of $47,305.50. Following the completion of the transaction, the director now owns 8,191 shares of the company’s stock, valued at approximately $149,895.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 42.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PDEX. Dimensional Fund Advisors LP increased its position in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after buying an additional 3,067 shares in the last quarter. Perritt Capital Management Inc. increased its position in Pro-Dex by 43.3% during the 1st quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 1,813 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after buying an additional 900 shares in the last quarter. Institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.